Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized
 nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by
 killing the cells or by stopping them from dividing. Radiation therapy uses high-energy
 x-rays to kill tumor cells. Erlotinib may make tumor cells more sensitive to radiation
 therapy. Giving carboplatin and paclitaxel albumin-stabilized nanoparticle formulation
 together with radiation therapy and erlotinib may kill more tumor cells.

 PURPOSE: This phase II trial is studying how well giving carboplatin and paclitaxel
 albumin-stabilized nanoparticle formulation together with radiation therapy and erlotinib
 works in treating patients with stage III non-small cell lung cancer that cannot be removed
 by surgery.
OBJECTIVES:

 Primary

 -  To determine the activity of induction chemotherapy comprising carboplatin and
 paclitaxel albumin-stabilized nanoparticle formulation followed by concurrent thoracic
 radiotherapy and erlotinib hydrochloride in patients with poor-risk, unresectable stage
 IIIA or IIIB non-small cell lung cancer.

 Secondary

 -  To determine the response rate and progression-free survival of these patients.

 OUTLINE: Patients receive induction chemotherapy comprising paclitaxel albumin-stabilized
 nanoparticle formulation IV over 30 minutes on days 1 and 8 and carboplatin IV over 30
 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease
 progression outside of the chest after induction therapy are removed from study. Patients
 with intrathoracic disease progression within the potential radiation field may continue
 protocol therapy at the discretion of the Study Chair. Patients with no disease progression
 outside the planned radiation field (either regional or distant) proceed to concurrent
 erlotinib hydrochloride and radiotherapy.

 Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily.
 Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions)
 in the absence of rapid disease progression outside of the chest or unacceptable toxicity.

 After completion of study therapy, patients are followed every 3 months for 1 year, and then
 every 6 months for up to 2 years
DISEASE CHARACTERISTICS:

 -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC),
 including any of the following histologies:

 -  Squamous cell carcinoma

 -  Adenocarcinoma (including bronchoalveolar cell)

 -  Large cell anaplastic carcinoma (including giant and clear cell carcinomas)

 -  Must meet the following criteria:

 -  T1-3 with N2 and selected N3*

 -  T4 with N0, N1, N2 and selected N3*

 -  M0 (no M1 patients) NOTE: *Patients with contralateral mediastinal disease (i.e.,
 N3) are eligible, provided all gross disease can be encompassed within the
 radiation boost field in accordance with the homogeneity criteria. Patients with
 ipsilateral scalene or supraclavicular disease are also eligible. Patients with
 contralateral hilar or supraclavicular node involvement are not eligible.

 -  Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20
 mm by conventional techniques or ≥ 10 mm by spiral CT scan

 -  Nonmeasurable lesions include the following:

 -  Bone lesions

 -  Leptomeningeal disease

 -  Ascites

 -  Pleural or pericardial effusion

 -  Abdominal masses that are not confirmed and followed by imaging techniques

 -  Cystic lesions

 -  Tumor lesions situated in a previously irradiated area

 -  Patients must be considered unresectable or inoperable AND be deemed candidates for
 combined modality therapy by a medical oncologist and a radiation oncologist

 -  Considered to be poor-risk with NCI CTC performance status (PS) 2 OR PS 0-1 and ≥ 10%
 weight loss within the past 3 months

 -  Patients with tumors adjacent to a vertebral body are eligible, provided all gross
 disease can be encompassed within the radiation boost field in accordance with the
 homogeneity criteria

 -  Pleural effusions meeting the following criteria allowed:

 -  Effusion is transudate, cytologically negative, and non-bloody

 -  Effusion can be seen on the chest CT scan but not on the chest x-ray AND is too
 small to tap

 -  Effusion appears only after a thoracotomy or other invasive thoracic procedure
 was attempted

 PATIENT CHARACTERISTICS:

 -  See Disease Characteristics

 -  Granulocytes ≥ 1,500/μL

 -  Platelet count ≥ 100,000/μL

 -  Creatinine ≤ 1.5 x upper limit of normal (ULN)

 -  AST < 2 x ULN

 -  Bilirubin ≤ ULN

 -  Not pregnant or nursing

 -  Negative pregnancy test

 -  Fertile patients must use effective contraception

 PRIOR CONCURRENT THERAPY:

 -  No prior chemotherapy or radiotherapy for NSCLC

 -  At least 2 weeks since formal exploratory thoracotomy

 -  No concurrent administration of sucralfate suspension and erlotinib hydrochloride

 -  No concurrent intensity-modulated radiotherapy

 -  No concurrent hormones or other chemotherapeutic agents except steroids given for
 adrenal failure, hormones administered for non-disease-related conditions (e.g.,
 insulin for diabetes), and intermittent use of dexamethasone as an antiemetic

 -  No concurrent palliative radiotherapy